AWST’s continuous flow ultracentrifuges efficiently and reliably separate viruses, virus like particles and viral vectors for the development and manufacture of vaccines, gene therapies, and other bio-products. From research scale to full production, the AWST patented core technology allows for linear scalability to full manufacturing scale with no revalidation or compromise of yield and purity. With the addition of the AWST Automated Fluid Handling (AFH), customers now have a system that fully automates and standardizes the critical process of fluid filling and fractionation in a self-contained mobile work station.